FeesSafety
Pluang+

Law firm probes Omeros over stock drops after EMA rejects drug approval twice

Market News
20 Oct 2026, 23:02 WIB
GlobeNewsWire
View Source
Bearish
Law firm probes Omeros over stock drops after EMA rejects drug approval twice

Pomerantz LLP is investigating Omeros Corporation for potential securities fraud following two significant stock price drops after the European Medicines Agency (EMA) twice rejected Omeros's drug narsoplimab for treating TA-TMA. The first rejection in June 2026 caused a nearly 20% stock fall, and a second negative opinion in October 2026 led to another nearly 14% drop. The investigation focuses on whether Omeros and its executives engaged in unlawful practices related to these announcements. Investors affected by these events are encouraged to contact the law firm for potential class action participation.

Omeros Corporation news is the subject, with Pluang market data providing context. For readers following health-sector stocks, 124 of 150 US stocks rose and 26 fell on October 21, 2026, at 03:11 WIB. Notable movers include LQDA at USD 36.53 (+7.03%, 81% Sell / 19% Buy), MRNA at USD 242.45 (+6.86%, 40% Sell / 60% Buy), and DFTX at USD 35.19 (+6.73%).

More News

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...

Market News
Bullish
3 hours ago
Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...

Bullish
3 hours ago
Okeanis Eco Tankers declares $7 dividend per share, payable December 1, 2026.

Okeanis Eco Tankers declares $7 dividend per share, payable December 1, 2026.

Okeanis Eco Tankers Corp announced a dividend of $7.00 per common share, approved on November 11, 2026. The dividend will be paid on December 1, 2026, with shares on the Oslo Stock Exchange and New York Stock Exchange having different ex-dividend dat...

Company Fundamentals
Neutral
5 hours ago
BitMine's Ether holdings valued $5.3B below purchase cost at fiscal year-end, showing a 26.6% paper loss.

BitMine's Ether holdings valued $5.3B below purchase cost at fiscal year-end, showing a 26.6% paper loss.

At the end of its fiscal year, BitMine's Ether (ETH) holdings were valued at $14.6 billion, which is $5.3 billion less than their original purchase cost of $19.9 billion. This represents a 26.6% valuation gap, meaning the current value is about 73.4%...

Protocol Fundamentals
Bearish
5 hours ago
Bitway surges 16.12% leading crypto gains as most major coins fall

Bitway surges 16.12% leading crypto gains as most major coins fall

Bitway (BTW) led gains among 90 large cryptocurrencies, rising 16.12% to $1.15, despite a broader market downturn where 62 of 90 assets fell. Other notable gainers included Gram (10.11%), Pi Network (8.51%), Lighter (7.32%), and Internet Computer (5....

Bearish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App